Finland innovation and china
- 1. Ilpo Kuronen www.hyvinvointiklusteri.fi www.kuopioinnovation.fi Health and Well-being Cluster Program Medical Device Gateway (MDG) A Chinese – Finnish network for commercialization of medical device technologies.
- 2. IDEA Europeanization of Chinese medical device technology through Finnish ventures. Opening up Chinese markets for Finnish medical device ventures. WinWin
- 3. OPPORTUNITY 6,3 billion $ 2,5 billion $ 2,5 billion $ IVD China 2007 Promising IVD Market in China There has not been a year in the last decade in which the IVD market in China has failed to grow. Combined with this impressive overall growth, a number of recent trends in the Chinese healthcare environment are making China an increasingly attractive and important market opportunity for in vitro diagnostics companies. Although there are a number of challenges for diagnostic manufacturers to understand and overcome, the market for clinical diagnostics in China (both reagents and instruments) remains one of the most promising emerging markets in the world. Meanwhile, the double-digit growth rate and opportunities for foreign firms will expand as China’s regulation of medical devices moves more in line with international practices. The State Food and Drug Administration of PRC (SFDA) promulgated the “Registration Management Act for In Vitro Diagnostics Reagent (Trial)” and put in force from June 1, 2007. It is widely expected that the future Chinese IVD market will become more regulated with clearer standards, enable further broadening and development of the industry segment.
- 4. OPPORTUNITY 6,3 billion $ 2,5 billion $ 2,5 billion $ Market Overview Emergence of Niche Segments Drives Growth in European IVD Market Valued at $6.60 billion in 2005, the European in-vitro diagnostics (IVD) market is expected to grow at a compound annual growth rate (CAGR) of 6.0 per cent from 2005 to 2012, reaching $9.95 billion in 2012. While well-established segments such as those for immunoassay and clinical chemistry currently contribute more than half of the market revenues, future market growth is likely to hinge on the immense potential of two niche segments, molecular biology and point-of-care testing (POCT). "Despite increasing price erosion, competition and industry consolidation as well as lack of sufficient reimbursements, the European IVD market is growing due to the emergence and rising adoption of molecular testing and near patient testing," notes the analyst of this research service. "The genomics revolution, combined with developments in automation technology, has definitely set the pace in this market." Major market participants are increasingly focusing on these potentially high-growth areas in an attempt to consolidate their positions in the IVD market. Despite growing maturity and fierce competition, leading participants continue to maintain a revenue growth of 3 to 5 per cent due to their market visibility, financial strength and customers’ brand loyalty. Growing Awareness and Adoption of Emerging Technologies Augurs Well for IVD Market An increase in the adoption of new technologies is likely to be a key factor driving the growth of the European IVD market over the forecast period. Awareness among patients and laboratories about emerging technologies is greater than ever before, especially in new areas such as molecular testing. Laboratories are realizing the need for automation and its many advantages. IVD manufacturers are cashing in on this trend and are actively working to innovate laboratory analyzers and other automated solutions as well as introduce novel technologies. In fact, the last decade has witnessed the emergence of numerous technologies that have gained popularity and carved a niche for themselves in the IVD market. "Established participants and many start-up companies are constantly refining and developing new technologies in this market," says the analyst. "These developments are more intense in areas such as molecular diagnostics and POCT." One of the major reasons behind these huge investments is the emergence of strong intellectual property (IP) laws. The potential of acquiring financial gains from IP patents is driving continuous innovation by many of the smaller companies, which might otherwise be wary of entering the fiercely competitive IVD market. Frost & Sullivan August 30, 2006
- 5. TECHNOLOGY IVD & IVDD - reagents - measuring devices - platforms - sensors - radiation devices - orthopedical devices - surgery devices Fitness & Health - measurement of physical condition
- 8. COMPETITORS 6,3 billion $ 2,5 billion $ 2,5 billion $ Ref: Medical product Outsourcing: June 2006
- 9. What creates value Change of: - Ideas - Innovations - Technology - Products - Outscoring opportunities
- 10. How to create value Acquisition of innovations New technology New products New sales REVENUE REVENUE New sales Old / tailored products Old innovation (technology) New opportunity
- 11. Why us? Born Global Sharon Ballard in Superchoaching® program (Jyväskylä 2008). “During my visit in Finland I have seen this problem so many times, Finns wake up, you have to think globally”. Do it faster What means to be the first in markets? “Hi big shark, I have an innovation, I can develop a device which is much fancier that the one which is offered by your competitor. It may take a few years to develop it but then we make business”. “Hi big shark, I have an idea and a business opportunity. To make business we need technology and fast. I know where to get it, are you interested in making business”.
- 12. Why program? Regulatory barriers SFDA is our primary strategic alliance since we must know what they expect from us. This program can establish good practices and contacts to get over regulatory hurdles faster. Finnish ventures are already placed products on EU markets under IVD Directive 79/98EU. Excising technology awaits for Europeanization which is an opportunity. Innovation channel: China Finland Medical industry is changing rapidly and new innovations must be placed on markets faster. If we don’t do it, someone else does. MDG program can create connections to Chinese research organizations and enterprises. These connections are valued as creation of new products and revenues.
- 13. Operations Direct contacts and visits to potential partners Strategic alliances conform the backbone of the program. The partners can be found from seminars, conferences, personal contacts etc. Our job is to locate the potential partners and lead them into the table. - SFDA (Chinese federal drug administration) - Leading Science Parks - Chinese technology provides - Chinese retail ventures (marketing & sales)
- 14. Financials Elucidation phase Contacting phase / operative actions Agreements, technology transfer, sales 2008 2009 2010 2000 € 20 000 € 200 000 €
- 15. Contact: Ilpo Kuronen, PhD Programme Director Kuopio Innovation Ltd B.O.Box 1188, FI-70211 Kuopio GSM +358 45 139 3757 ilpo.kuronen@kuopioinnovation.fi